Jeffrey L Saver1, Jeffrey Gornbein, Sidney Starkman. 1. Stroke Center and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Calif 90095, USA. jsaver@ucla.edu
Abstract
BACKGROUND AND PURPOSE: Multiple statistical analyses of the 2 NINDS-tPA trials have confirmed study findings of benefit of fibrinolytic therapy. A recent graphic analysis departed from best practices in the visual display of quantitative information by failing to take into account the skewed functional importance of NIH Stroke Scale raw scores and by scaling change axes at up to 20 times the range achievable by individual patients. METHODS: Using the publicly available datasets of the 2 NINDS-tPA trials, we generated a variety of figures appropriate to the characteristics of acute stroke trial data. RESULTS: A diverse array of figures all visually delineated substantial benefits of fibrinolytic therapy, including: bar charts of normalized gain and loss; stacked bar, bar, and matrix plots of clinically relevant ordinal ranks; a time series stacked line plot of continuous scale disability weights; and line plot, bubble chart, and person icon array graphs of joint outcome table analysis. The achievable change figure showed substantially greater improvement among tPA than placebo patients, median 66.7% (interquartile range, 0 to 92.0) versus 50.0% (interquartile range, -7.1 to 80.0), P=0.003. CONCLUSIONS: On average, under 3 hour patients treated with tPA recovered two-thirds while placebo patients improved only half of the way toward fully normal. Graphical analyses of the 2 NINDS-tPA trials, when performed according to best practices, is a useful means of conveying details about patient response to therapy not fully delineated by summary statistics, and confirms a valuable treatment benefit of under 3 hour fibrinolytic therapy in acute stroke.
BACKGROUND AND PURPOSE: Multiple statistical analyses of the 2 NINDS-tPA trials have confirmed study findings of benefit of fibrinolytic therapy. A recent graphic analysis departed from best practices in the visual display of quantitative information by failing to take into account the skewed functional importance of NIH Stroke Scale raw scores and by scaling change axes at up to 20 times the range achievable by individual patients. METHODS: Using the publicly available datasets of the 2 NINDS-tPA trials, we generated a variety of figures appropriate to the characteristics of acute stroke trial data. RESULTS: A diverse array of figures all visually delineated substantial benefits of fibrinolytic therapy, including: bar charts of normalized gain and loss; stacked bar, bar, and matrix plots of clinically relevant ordinal ranks; a time series stacked line plot of continuous scale disability weights; and line plot, bubble chart, and person icon array graphs of joint outcome table analysis. The achievable change figure showed substantially greater improvement among tPA than placebo patients, median 66.7% (interquartile range, 0 to 92.0) versus 50.0% (interquartile range, -7.1 to 80.0), P=0.003. CONCLUSIONS: On average, under 3 hour patients treated with tPA recovered two-thirds while placebo patients improved only half of the way toward fully normal. Graphical analyses of the 2 NINDS-tPA trials, when performed according to best practices, is a useful means of conveying details about patient response to therapy not fully delineated by summary statistics, and confirms a valuable treatment benefit of under 3 hour fibrinolytic therapy in acute stroke.
Authors: M Sharma; H Clark; T Armour; G Stotts; R Coté; M D Hill; A M Demchuck; D Moher; C Garritty; F Yazdi; K Lumely-Leger; M Murdock; M Sampson; N Barrowman; G Lewin Journal: Evid Rep Technol Assess (Summ) Date: 2005-07
Authors: Heinrich J Audebert; Johannes Schenkel; Peter U Heuschmann; Ulrich Bogdahn; Roman L Haberl Journal: Lancet Neurol Date: 2006-09 Impact factor: 44.182
Authors: Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks Journal: Stroke Date: 2007-04-12 Impact factor: 7.914
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: Erik Cobo; Julio J Secades; Francesc Miras; José Antonio González; Jeffrey L Saver; Cristina Corchero; Roser Rius; Antoni Dàvalos Journal: Stroke Date: 2009-12-24 Impact factor: 7.914
Authors: Shashank Agarwal; Erica Scher; Aaron Lord; Jennifer Frontera; Koto Ishida; Jose Torres; Sara Rostanski; Eva Mistry; Brian Mac Grory; Shawna Cutting; Tina Burton; Brian Silver; Ava L Liberman; Mackenzie P Lerario; Karen Furie; James Grotta; Pooja Khatri; Jeffrey Saver; Shadi Yaghi Journal: Stroke Date: 2020-02-27 Impact factor: 7.914
Authors: Theresa I Shireman; Kaijun Wang; Jeffrey L Saver; Mayank Goyal; Alain Bonafé; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Reza Jahan; Katherine A Vilain; John House; Jin-Moo Lee; David J Cohen Journal: Stroke Date: 2016-12-27 Impact factor: 7.914
Authors: George Howard; Jennifer L Waller; Jenifer H Voeks; Virginia J Howard; Edward C Jauch; Kennedy R Lees; Fenwick T Nichols; Volker W Rahlfs; David C Hess Journal: Stroke Date: 2012-02-16 Impact factor: 7.914
Authors: Alex H S Harris; Nicolas B Barreto; Amber W Trickey; Sylvia Bereknyei; Tong Meng; Todd H Wagner; Prasanthi Govindarajan Journal: Implement Sci Commun Date: 2020-06-05